FDA ‘reset’ continues with new plan for reviewing rare disease drugs

T2Covered by 2 sources · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 15 Oct, 15:23 UTC

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

devscience

Sources

• T2FDA ‘reset’ continues with new plan for reviewing rare disease drugsBioPharma Dive / Healthcare Dive / MedTech Dive15 Oct, 15:23
• T2FDA ‘reset’ continues with new plan for reviewing rare disease drugsBioPharma Dive / Healthcare Dive / MedTech Dive15 Oct, 15:23